In Patients Treated by Selective Internal Radiotherapy, Cellular In Vitro Immune Function Is Predictive of Survival.
Aglaia DomouchtsidouFerdinand BeckmannBeate MarenbachStefan P MuellerJan BestKen HerrmannPeter A HornVahé BarsegianMonika LindemannPublished in: Cancers (2023)
In patients with liver malignancies, the cellular immune function was impaired in vitro after selective internal radiotherapy (SIRT). Because immunosuppression varied substantially, in the current study, we investigated in 25 SIRT patients followed up for ten years whether the lymphocyte function was correlated with survival. Peripheral blood mononuclear cells were stimulated with four microbial antigens (tuberculin, tetanus toxoid, Candida albicans and CMV) before therapy and at four time points thereafter, and lymphocyte proliferation was determined by H3-thymidine uptake. The median sum of the responses to these four antigens decreased from 39,464 counts per minute (CPM) increment (range 1080-204,512) before therapy to a minimum of 700 CPM increment on day 7 after therapy (0-93,187, p < 0.0001). At all five time points, the median survival in patients with weaker responses was 2- to 3.5-fold shorter ( p < 0.05). On day 7, the median survival in patients with responses below and above the cutoff of a 2 CPM increment was 185 and 523 days, respectively (χ 2 = 9.4, p = 0.002). In conclusion, lymphocyte function could be a new predictor of treatment outcome after SIRT.
Keyphrases
- signaling pathway
- candida albicans
- peripheral blood
- early stage
- oxidative stress
- free survival
- end stage renal disease
- ischemia reperfusion injury
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- radiation induced
- locally advanced
- biofilm formation
- escherichia coli
- prognostic factors
- peritoneal dialysis
- immune response
- staphylococcus aureus
- cystic fibrosis
- high resolution
- atomic force microscopy
- replacement therapy
- combination therapy